Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda

4 days ago 2

• Healthcare

Lisa Maree Williams/Getty Images News

Summit Therapeutics (NASDAQ:SMMT) shares spiked on Thursday, triggering a trading halt after Bloomberg News reported that AstraZeneca (NASDAQ:AZN) is in discussions to strike a licensing deal with the company for its lung cancer drug ivonescimab, a potential rival

Recommended For You

1. Homepage
2. Politics
3. Summit said to be in talks with Astra to license potential rival for Merck’s Keytruda